Onkologie. 2025:19(1):29-32 | DOI: 10.36290/xon.2025.007

Second-line therapy for KRAS-positive metastatic non-small cell lung cancer

Martin Svatoň

Klinika pneumologie a ftizeologie, FN Plzeň

Non-small cell lung cancer (NSCLC) with a KRAS mutation is the most common type of lung tumour with a sensitive mutation. At the same time, KRAS mutation is associated with a poor prognosis for patients. Therefore, the outlook for longer survival of patients with KRAS-mutated metastatic NSCLC has not been good for a long time. However, the prognosis of these patients has changed dramatically in recent years. The possibility of immunotherapy treatment as well as targeted treatment using tyrosine kinase inhibitors for the KRAS G12C point mutation has increased prognosis of this patients. The article presents these option of targeted therapy for the second line of treatment and also points out a comparison with previously used chemothe­rapy. The possibility of developing resistance to targeted treatment is also discussed. Last but not least, the text also describes the prospects for the near future with the expansion of targeted treatment options beyond the KRAS G12C point mutation.

Keywords: NSCLC, KRAS, sotorasib, adagrasib, immunotherapy.

Accepted: February 27, 2025; Published: March 10, 2025  Show citation